
| Disease Domain | Count |
|---|---|
| Hemic and Lymphatic Diseases | 1 |
| Neoplasms | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 1 |
| Top 5 Target | Count |
|---|---|
| Class IIA HDACs(Histone deacetylases, class IIA) | 1 |
Target |
Mechanism Class IIA HDACs inhibitors [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Sep 2025 |
Sponsor / Collaborator University of Bern [+5] |
Start Date01 Oct 2024 |
Sponsor / Collaborator [+2] |
Start Date30 Sep 2024 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
TMP269 ( Class IIA HDACs ) | Acute Myeloid Leukemia More | Preclinical |





